Across all tumor types, anti-PD-1/PD-L1 therapy results in response rates of 36–100% in patients with PD-L1-positive tumors, whereas in those with PD-L1-negative tumors, response rates range from 0 to 17% (Patel and Kurzrock, 2015). The gene discussed is CD274; the disease is neoplasm.